**Patients with MCL**

**Post-BTK Inhibitor Failure Face Poor Prognoses**

Regain control with TECARTUS™ with an ORR of **93%** with TECARTUS®

*(Primary endpoint, in the primary analysis set (N=60)†)*

**In the primary analysis set (N=60) at 12.3 months:**

- **Effective**
  - Primary endpoint: Percentage of patients with an objective response (CR or PR)†

- **Durable**
  - Secondary endpoint: DOR†
    - The median duration of response was not reached (95% CI: 8.6-NE) at a median follow-up of 12.3 months in the primary efficacy analysis set.
    - In the patients with ≥2 years follow-up, 43% (N=12/28) remained in remission.

- **Tolerability**
  - Tecartus led to serious and life-threatening toxic events of the type reported with other anti-CD19 CAR T-cell therapies.† The most significant and frequently occurring adverse reactions were cytokine release syndrome (91%), infections (55%), and encephalopathy (51%).†

Regain control with Tecartus at [www.kitecartforum.co.uk](http://www.kitecartforum.co.uk) (This website contains promotional content)

---

**References:**

1. Tecartus. Summary of Product Characteristics. 2. Wang M, Muneo J, Goy A, et al. KITE-195 CAR T-cell therapy in relapsed/refractory mantle cell lymphoma. N Engl J Med 2020; 384(14):1313-1324. 3. Smith A, Ramani E, Appelbaum F, et al. Impact of novel therapies for mantle cell lymphoma in the real-world setting: a report from the UK’s Haematological Malignancy Network (HMHN). Br J Haematol 2014;165(1):12-20. 4. Smith A, Ramani E, Appelbaum F, et al. Impact of novel therapies for mantle cell lymphoma in the real-world setting: a report from the UK’s Haematological Malignancy Network (HMHN)—supplementary appendix. Br J Haematol 2018;179(1):15-23.

© 2020 Kite Pharma, Inc. All rights reserved. KITE-195-01-0015.

Date of preparation: February 2021
Transfusion management of severe anaemia in African children: a consensus algorithm

Kathryn Maitland, 1, 7 Sarah Kiguli, 2 Peter Olupot-Olupot, 1 Robert O. Opoka, 2 Yami Chimalizeni, 4 Florence Alaroker, 5 Sophie Uyoga, 6 Dorothy Kyeiye-Byabazaire, 7 Bridon M’baye, 8 Imelda Bates, 9 Thomas N. Williams, 1, 6 Deogratias Munube, 2 Dora Mbanya, 10 Elizabeth M. Molyneux, 4 Annabelle South, 11 A. Sarah Walker, 11 Diana M. Gibb, 11 Elizabeth C. George 11 and TRACT Stakeholders meeting group

1 Department of Infectious Disease, Division of Medicine, Institute of Global Health and Innovation, Division of Medicine, Imperial College, London, UK, 2 Department of Paediatrics and Child Health, School of Medicine, Makerere University and Mulago Hospital, Kampala, 3 Faculty of Health Sciences, Busitema University, Mbale Regional Referral Hospital, Mbale, Uganda, 4 College of Medicine, Malawi-Liverpool-Wellcome Research Programme, Blantyre, Malawi, 5 Soroti Regional Referral Hospital, Soroti, Uganda, 6 Kenya Medical Research Institute (KEMRI)/Wellcome Trust Research Programme, Kilifi, Kenya, 7 Uganda Blood Transfusion Services (BTS), National BTS, Kampala, Uganda, 8 Malawi BTS, Blantyre, Malawi, 9 Liverpool School of Tropical Medicine, Liverpool, UK, 10 Haematology & Transfusion Service, Centre Hospitalier et Universitaire, Yaounde, Cameroon, and 11 Medical Research Council Clinical Trials Unit (MRC CTU), University College London, London, UK

Summary

The phase III Transfusion and Treatment of severe anaemia in African Children Trial (TRACT) found that conservative management of uncomplicated severe anaemia [haemoglobin (Hb) 40–60 g/l] was safe, and that transfusion volume (20 vs. 30 ml/kg whole blood equivalent) for children with severe anaemia (Hb < 60 g/l) had strong but opposing effects on mortality, depending on fever status (>37.5°C). In 2020 a stakeholder meeting of paediatric and blood transfusion groups from Africa reviewed the results and additional analyses. Among all 3196 children receiving an initial transfusion there was no evidence that nutritional status, presence of shock, malaria parasite burden or sickle cell disease status influenced outcomes or modified the interaction with fever status on volume required. Fever status at the time of ordering blood was a reliable determinant of volume required for optimal outcome. Elevated heart and respiratory rates normalised irrespective of transfusion volume and without diuretics. By consensus, a transfusion management algorithm was developed, incorporating three additional measurements of Hb post-admission, alongside clinical monitoring. The proposed algorithm should help clinicians safely implement findings from TRACT. Further research should assess its implementation in routine clinical practice.

Keywords: anaemia, African children, transfusion, guidelines, malaria.
Introduction

In sub-Saharan Africa, children admitted to hospital with severe anaemia [defined as a haemoglobin (Hb) of <60 g/l] present a major public health burden on in-patient and blood transfusion services. Although timely transfusion is frequently lifesaving, equitable access to adequate supplies of safe blood remains a key challenge. In 2013 the World Health Organization (WHO) Global Database on Blood Safety reported that <5 units of blood were donated per 1000 people in most African countries, far fewer than estimated requirements of 20 units/1000 per year. Despite considerable investment by external funders in the decade since their previous report (2004–2005), few countries had made significant improvements in their collection rates.

Guidelines developed by the WHO encourage the conservative use of blood in children, restricting routine transfusion to those with severe anaemia, defined as an Hb <40 g/l, or 40–60 g/l with clinical signs of severity. However, the underpinning evidence base for this recommendation is weak and adherence to these guidelines is poor, which is compounded by inconsistent Hb threshold recommendations for transfusion for malaria. Currently, 20 ml/kg of whole blood (or 10 ml/kg of packed cells) is recommended for severe anaemia. However, if standard formulae for transfusion volume were applied, the one-size-fits-all 20 ml/kg recommendation would underestimate transfusion requirements by ~30%. A consensus international guideline on transfusion of critically ill children also noted a weak global evidence base and specifically highlighted the need to evaluate optimal transfusion volumes.

The Transfusion and Treatment of Severe Anaemia in African Children Trial (TRACT) was designed as a multicentre trial to establish transfusion and treatment strategies in sub-Saharan Africa and investigated: (i) whether an immediate transfusion in children with uncomplicated severe anaemia (Hb 40–60 g/l) would improve outcomes and (ii) whether 30 versus 20 ml/kg whole blood might improve outcomes, defined as mortality to day 28 (primary outcome) and day 180, and the need for additional transfusions and relapse of severe anaemia.

The trial results, published in two linked manuscripts in 2019, showed that an immediate transfusion is not required in children with uncomplicated severe anaemia (Hb 40–60 g/l without severity features), as long as children are monitored for progression to the development of severe and/or complicated anaemia during their initial hospital stay; such progression occurred in 49% of trial participants who then received a transfusion. The results also showed that giving larger volumes of blood, 30 ml/kg whole blood equivalent versus the 20 ml/kg recommended in the current WHO guidelines, to children with severe anaemia who did not have a fever (axillary temperature ≤37.5°C, measured at screening) halved the number of deaths by 28 days [hazard ratio (HR) 0.43, 95% confidence interval (CI) 0.27–0.69]. However, the opposite occurred in children who were febrile (>37.5°C) at screening; 30 ml/kg whole blood equivalent almost doubled the risk of death in comparison to children who received the lower, 20 ml/kg, volume (HR 1.91, 95% CI 1.04–3.49; P value for heterogeneity of effect on mortality P = 0.00009).

The TRACT results provide an evidence base with potential to improve outcomes for children with severe anaemia. Furthermore, initial economic analyses also suggested that if the results were implemented and adhered to by clinicians, there could be substantial cost savings for blood transfusion services. To explore this further, the TRACT investigators shared results from the trial with key stakeholders at a meeting in Uganda in February 2020, co-hosted by the African Society for Blood Transfusion and the Ugandan Paediatric Association. The meeting was attended by stakeholders from 12 sub-Saharan countries and included representatives from blood transfusion services, health service providers (including paediatricians involved in providing continued professional development and training courses) and representatives from international policymakers, including the WHO and Médecins Sans Frontières (Appendix 1). Our aim was to clarify current practice in different settings within Africa, to discuss the implications of the TRACT findings from a stakeholder perspective, to identify potential barriers to their uptake and to identify any additional requirements that might be needed to support their safe implementation, including further analyses of the TRACT data.

A major output from discussions at this stakeholder meeting was the development of a transfusion management algorithm for future implementation, which was agreed by consensus. Here, we present the algorithm and the additional analyses that support it.

Methods

A summary of the trial and statistical methods is available in the supplemental appendix. Blood transfusions were supplied by the local blood transfusion services (BTS), which included three blood component types: (i) whole blood (WB), collected from donors and stored without any preparation or via transfer bags into smaller bags of whole blood (known as 'Pedi-Packs'); (ii) packed red cell concentrates (RCC), produced by centrifugation to remove platelets and plasma, followed by the addition of sodium, adenine, glucose and mannitol solution; and (iii) RCC created using gravity (Uganda only). To support the algorithm, we investigated detailed response to transfusion volume and requirement for additional transfusions. At the request of participants at the meeting we provided original and further analyses of the primary outcome (28-day mortality) in the following key subgroups: (i) nutritional status (protocol defined); (ii) malaria status including those with high malaria burdens (plasma Plasmodium falciparum histidine-rich protein 2 (PfHRP2) concentration of >1000 ng/ml); (iii) children with shock defined by the Fluid Expansion As Supportive Therapy in
critically ill African children (FEAST) trial eligibility criteria; and those with sickle cell disease (SCD). These subgroups all have direct implications for the current WHO management guidelines. Finally, additional exploration of the fever/no fever interaction was undertaken for a number key subgroups where the interaction might potentially have been impacted for physiological reasons [including SCD and Blackwater fever (haemoglobinuria)].

Results

The TRACT recruited children aged 2 months to 12 years presenting to hospital with both uncomplicated and complicated severe anaemia (Fig 1), and the algorithm is aimed at this population (Fig 2). We found no evidence to show that outcome was affected by nutritional status (including children classified as undernourished) or by SCD status (which was unknown at the time of randomisation in the majority) (Fig 3A). In the current WHO guidelines, malaria hyperparasitaemia is an indicator for immediate transfusion. We therefore assessed whether this was supported by the TRACT. Instead of ‘hyperparasitaemia’, we used the value PfHRP2 ≥1000 ng/ml, a parameter that more accurately reflects the highest total parasite burden, and which distinguishes ‘true’ severe malarial anaemia from anaemia in the presence of incidental parasitaemia. We found that outcome was the same in children managed on a deferred transfusion protocol as in those receiving immediate transfusion (Fig 3A). Thus, in our algorithm we did not provide separate recommendations with regard to immediate or deferred transfusion for these groups.

For the higher versus lower volume comparison, the stakeholder meeting group identified two subgroups that could, potentially, have increased the risk of a worse outcome with higher transfusion volumes, irrespective of fever status: (i) children with clinical features of shock (severely impaired perfusion as defined in FEAST trial); and (ii) children with anthropometric features of undernutrition. As shown in Fig 3B none of these subgroups had outcomes that differed significantly from the overall findings. Therefore, the stakeholder meeting concluded that the recommendations on transfusion volume did not need to differ according to a child’s perfusion status, nutrition status or malaria parasite burden.

The initial evaluation of a child with suspected severe anaemia should include a Hb test, axillary (or other) temperature, weight and assessment for severity signs (altered conscious level or respiratory distress). Then the child can be grouped into one of three categories: (i) severe and complicated anaemia (Hb <40 g/l or Hb 40–60 g/l, with clinical severity features); (ii) Hb 40–60 g/l, without clinical severity features; and (iii) Hb >60 g/l, with or without severity signs. The first group require immediate transfusion; the second group do not require immediate transfusion but should have a blood sample sent to the transfusion services for blood ABO grouping and blood unit(s) (WB or RCC) saved while being monitored both clinically and for Hb level (at a minimum of 8, 24 and 48 h following identification). The volume for transfusion, based on weight and temperature can be obtained from Table I. The third group does not require transfusion (with Hb >60 g/l) and can be managed without further Hb monitoring (Fig 2). Once children have been transfused, or for stable children with Hb 40–60 g/l, they will continue to be monitored and further transfusion management will depend on their latest Hb and/or clinical features.

Blood volume dosing table

In the TRACT, we were reassured that >96% of children received the correct volume of blood. Children weighed between 5 and 35 kg, the majority (~75%) weighing ≤15 kg. Thus, most of the WB prescriptions for the 20 ml/kg strategy were between 100 and 320 ml and for the 30 ml/kg strategy were between 150 and 480 ml. To simplify future implementation of the algorithm, we have generated a simplified ‘look-up’ chart together with bag size recommendations for WB Pedi-Packs for appropriate weight bands (Table I Blood dosing chart). If WB is unavailable then the equivalent RCC doses are half the doses stated in the ‘look-up’ chart. This is intended to be used alongside the transfusion algorithm.

Timing and stability of fever

For children with severe or complicated anaemia, the volume of blood component ordered (20 or 30 ml/kg WB) in the algorithm is dependent on the axillary temperature at the time of requesting blood. For those with uncomplicated anaemia that subsequently need a transfusion, the axillary temperature at the time of ordering blood would be used. In the TRACT trial nearly all children (3106/3196, 97.2%) had a history of fever in the current illness, but only 1253 (39.2%) had a recorded fever at screening, before the receipt of a transfusion. Screening temperature is only at one time point, so we examined the patterns of fever during their hospital stay and found only 10% of children without a fever at screening developed one after the transfusion had started. For children with a fever at screening, the fever had waned in 80% by 16 h (Fig 5). The heterogeneity in the estimate of mortality remained for groups defined by their fever status over 8 h (Fig 5; Figure S2) with benefit from 30 ml/kg for those with no fever at screening, even if they had intermittent fever during the subsequent 8 h. However, if a child subsequently required new or additional transfusion then the group recommended that the axillary temperature at the time of requesting blood would be used to indicate volume required, rather than the initial fever status at initial screening.

What might be the mechanisms for excess mortality in children receiving 30 ml/kg with fever?

We found no strong evidence implicating any specific cause for the excess mortality associated with fever and blood
Neither known SCD nor haemoglobinuria at admission had any effect on the fever/transfusion volume interaction, nor did the age of the child (Figure S1). Transfusion-related volume overload [pulmonary oedema, transfusion-related lung injury (TRALI) or transfusion-associated cardiac overload (TACO)] was ruled out because of the small

---

Fig 1. Transfusions given in the TRACT trial.
number of solicited events \((n = 5)\) in the trial (summarised in Table S1); only one was adjudicated to be probably related to blood volume. No child received diuretics or other anti-failure medications. The recovery of elevated heart and respiratory rates occurred similarly in both febrile and afebrile groups (Figure S3). Blood component type (WB or RCC) was also explored in a pre-planned sub-analysis of the TRACT and was found not to have contributed to adverse outcomes. The stakeholders supported the algorithm recommending both 30 and 20 ml/kg transfusion WB volumes (or RCC equivalent), depending on fever status.

**Children in the no immediate transfusion category: what triggered transfusion and when was it given?**

Children with uncomplicated severe anaemia (no severity signs and Hb 40–60 g/l) would be monitored clinically according to the algorithm, with a Hb test at 8, 24 and 48 h and not transfused unless they develop severity signs or Hb <40 g/l. In the TRACT trial 386/787 (49%) children randomised to not receive an immediate transfusion, subsequently did receive one; details of timing of triggered transfusions are in Figs 1 and 4A. Haemodilution, by liberal use of intravenous fluids, was discounted, based on the fact...
Severe illness: respiratory distress or impaired consciousness. Impaired perfusion: one or more of the following: capillary refill >2s, temperature gradient, weak pulse or severe tachycardia. 293 children were not febrile at admission but had history of fever, severe illness and impaired perfusion and so are included in the eligible group.

Undernourished: one or more of mid-upper arm circumference (MUAC) ≥ 11·0cm – 11.9cm (children aged 2 to 6 months) or MUAC ≥ 11·5cm – 12.4 (children aged 6 months to 59 months) or Weight for Height Z score ((WHZ) < -3 or Weight for Age Z score (WAZ) if height not recorded) or presence of kwashiorkor at any age.

Malnourished: one or more of mid-upper arm circumference (MUAC) < 11·0cm (children aged 2 to 6 months) or MUAC < 11·5cm (children aged 6 to 59 months) or Weight for Height Z score ((WHZ) < -3 or Weight for Age Z score (WAZ) if height not recorded) or presence of kwashiorkor at any age.

Fig 3. (A) Morality at 28 days by subgroups for the immediate vs control timing of transfusion comparison. (B) Morality at 28 days by subgroups for the transfusion volume comparison. PfHRP2, plasma Plasmodium falciparum histidine-rich- protein 2.
| Weight, kg | 20 ml/kg | Component† Volume | Min, ml/kg | Mid, ml/kg | Max, ml/kg | Component‡ Volume | Min, ml/kg | Mid, ml/kg | Max, ml/kg |
|-----------|----------|-------------------|------------|------------|------------|-------------------|------------|------------|------------|
| 5         | 6        | 100               | 16-7       | 18-2       | 20-0       | 150               | 25-0       | 27-3       | 30-0       |
| 6         | 7        | 150               | 21-4       | 23-1       | 25-0       | 200               | 28-6       | 30-8       | 33-3       |
| 7         | 8        | 150               | 18-8       | 20-0       | 21-4       | 200               | 25-0       | 26-7       | 28-6       |
| 8         | 9        | 150               | 16-7       | 17-6       | 18-8       | 250               | 27-8       | 29-4       | 31-3       |
| 9         | 10       | 200               | 20-0       | 21-1       | 22-2       | 300               | 30-0       | 31-6       | 33-3       |
| 10        | 11       | 200               | 18-2       | 19-0       | 20-0       | 300               | 27-3       | 30-0       | 30-0       |
| 11        | 12       | 200               | 16-7       | 17-4       | 18-2       | 350               | 29-2       | 30-4       | 31-8       |
| 12        | 13       | 250               | 19-2       | 20-0       | 20-8       | 400               | 30-8       | 32-0       | 33-3       |
| 13        | 14       | 250               | 17-9       | 18-5       | 19-2       | 400               | 28-6       | 29-6       | 30-8       |
| 14        | 15       | 300               | 20-0       | 20-7       | 21-4       | 450               | 30-0       | 31-0       | 32-1       |
| 15        | 16       | 300               | 18-8       | 19-4       | 20-0       | 450               | 28-1       | 29-0       | 30-0       |
| 16        | 17       | 300               | 17-6       | 18-2       | 18-8       | 500               | 29-4       | 30-3       | 31-3       |
| 17        | 18       | 350               | 19-4       | 20-0       | 20-6       | 500               | 27-8       | 28-6       | 29-4       |
| 18        | 19       | 350               | 18-4       | 18-9       | 19-4       | 550               | 28-9       | 29-7       | 30-6       |
| 19        | 20       | 400               | 20-0       | 20-5       | 21-1       | 600               | 30-0       | 30-8       | 31-6       |
| 20        | 21       | 400               | 19-0       | 19-5       | 20-0       | 600               | 28-6       | 29-3       | 30-0       |
| 21        | 22       | 400               | 18-2       | 18-6       | 19-0       | 650               | 29-5       | 30-2       | 31-0       |
| 22        | 23       | 450               | 19-6       | 20-0       | 20-5       | 650               | 28-3       | 28-9       | 29-5       |
| 23        | 25       | 450               | 18-8       | 19-1       | 19-6       | 700               | 29-2       | 29-8       | 30-4       |
| >25       | 450      | Adult pack        | 18-0       | 18-4       | 18-8       | 700               | 28-0       | 28-6       | 29-2       |

Shaded rows are WHO standard weight bands.

*If whole blood packs are not available use red cell concentrate (RCC)/packed cells at half the volume, e.g. 20 ml/kg whole blood is equivalent to 10 ml/kg RCC.
†If multiple blood components are needed then pragmatically these can be obtained from multiple donors if a single donor component is insufficient.
that no fluid boluses were given\(^\text{17}\) and children only received maintenance fluids until they were able to drink. Compared to children randomised to immediate transfusion, who received blood at a median [interquartile range (IQR)] of 1–3 [0–9–1.7] h after randomisation, 295/386 (76%) of those in the deferred group received a subsequent transfusion, principally triggered by a fall in Hb to <40 g/l, at a median (IQR) of 24.9 [9.2–49.8] h after randomisation. Reasons for transfusion in an additional 57 (15%) children were the development of clinical severity features (impaired consciousness or increased work of breathing) and SCD identified in hospital (n = 7; 2%). Only 27 (7%) had a transfusion without a very low Hb or a recorded severity feature, largely after 48 h when reasons for transfusions were not routinely captured. Of note, the timing of triggered transfusions largely coincided with the routine Hb assessment in the trial (at 8, 16, 24 and 48 h after randomisation) and 49% were given within 24 h (excluding the 24 assessment) (Fig 4A). A further two Hb measurements (at 36 and 48 h) would have identified around two-thirds (249/386; 64.5%) of children in the control group who subsequently received a transfusion. Thus, this informed the recommendation in the algorithm for repeat Hb measurements at 8, 24 and 48 h (Fig 2), with additional measurements at 16 and 36 h where resources permit.

Timing of deaths in controls: concern that this may be related to delaying transfusion

Of the 13 children in the control arm who died, 10 had received a transfusion prior to death and these were received at a median of 9 h after randomisation.\(^\text{13}\) Furthermore, of seven children transfused before 10 h, one died on Day 1 (who had a screening Hb of 59 g/l) and six died between days 4–23, with a recorded 48-h Hb level of 50–90 g/l (only two were <60 g/l). Three were not transfused; one died on day 1 with last recorded Hb of 46 g/l, while two died on day 6 and day 25 with 48-h Hb levels of 54 and 65 g/l respectively. In summary, delay in transfusion or no receipt of blood occurred earlier and at a higher rate in those randomised to 20 ml/kg. Approximately 5% of children in this group received a transfusion by 24 h and 9–10% by 48 h, compared to under half this rate at both time points in the 30 ml/kg arm (Fig 4B). Although it was the second most common reason for a second transfusion, SCD status (known or unknown) was not a risk factor for poor outcome, this group was not segregated in the algorithm for repeat transfusions, they occurred earlier and at a higher rate in those randomised to 20 ml/kg. Approximately 5% of children in this group received a transfusion by 24 h and 9–10% by 48 h, compared to under half this rate at both time points in the 30 ml/kg arm (Fig 4B). Although it was the second most common reason for a second transfusion, SCD status (known or unknown) was not a risk factor for poor outcome, this group was not segregated in the algorithm for repeat transfusion.

Consensus blood transfusion algorithm

Following discussion of all of the above, the meeting participants endorsed the proposed paediatric blood transfusion algorithm based on the evidence provided by the TRACT (Fig 2). The key elements start with triage of a child with suspected severe anaemia, incorporating an assessment of severity (to determine the need for a transfusion), with further management guided initially by an assessment of Hb (or haematocrit if Hb is not possible) and fever status at the time a blood transfusion is ordered from the blood transfusion service, in order to determine whether to request a higher volume of blood (30 ml/kg WB or 15 ml/kg RCC), or standard volume (20 ml/kg WB or 10 ml/kg RCC) if fever is present. Informed by the main time points when first (for children with uncomplicated anaemia) or repeat transfusions occurred, our proposed algorithm also incorporates a minimal number of additional measurements of Hb (or haematocrit) and clinical monitoring.

Discussion

If fully implemented, our proposed paediatric blood transfusion algorithm could avert the need for immediate transfusion in children with severe uncomplicated anaemia (including those with SCD) and provide higher volumes of blood to children with severe and complicated anaemia (based on clinical signs and severity of anaemia) who do not have a fever. Both these strategies would improve clinical outcomes, more specifically, in children without a fever, a liberal 30 ml/kg strategy would result in almost 60% fewer children dying, while for children with a fever a conservative 20 ml/kg strategy would prevent a 50% higher mortality were...
Fig 4. (A) Time to Transfusion in Immediate vs Control Comparison. (B) Cumulative incidence in second transfusion in the 30 ml/kg vs. 20 ml/kg split by fever and no fever. Note: A competing risks analysis with discharge, absconding and death as competing events. There are 39 transfusions given after 120 h from baseline not included on the graph. [Colour figure can be viewed at wileyonlinelibrary.com]
they to receive the higher volume. Although more complex, the TRACT showed that this approach could substantially reduce the demand for paediatric transfusion because the higher volumes given to children without fever would also significantly reduce the number of additional transfusions required. Our previous cost-effectiveness analysis indicated substantial savings for health services, with 60% reduction in blood transfusion required compared to immediate transfusion for all children with uncomplicated severe anaemia (Hb <60 g/l).13 The unadjusted cost-effectiveness analyses, presented in the trial reports, demonstrated that the ‘no immediate transfusion strategy’ would cost $66–46 (American dollars) per child in comparison to $72–09 per child for an immediate transfusion strategy: the Meeting attendants recognised that the cost savings would be even greater where per-unit costs of donor blood are higher.

It was recognised that implementation of the algorithm in a real-life setting is required, in order to establish feasibility, NB: excludes children who died prior to 8 hours (n=36) and 1 child that absconded. Time at risk from 8 hours onwards.

Fig 5. Justification for transfusion volume management based on initial temperature and not on subsequent temperatures.

### Table II. What were the indications for second transfusions by volume randomisation and by fever status?

| Indication (at any time during admission) | Second transfusions for those randomised to transfusion arms, n (%) |
|------------------------------------------|---------------------------------------------------------------|
|                                         | Overall (n = 496†) | 20 ml with fever* (n = 123) | 20 ml without fever (n = 177) | 30 ml with fever* (n = 83) | 30 ml without fever (n = 113) |
| New Hb <40 g/l                           | 185 (37)           | 45 (37)                       | 82 (46)                        | 18 (22)                      | 40 (35)                       |
| New severity signs‡ and Hb 40–60 g/l     | 9 (2)              | 3 (2)                         | 1 (<1)                         | 2 (2)                        | 3 (3)                         |
| Known SCD or haemoglobinuria and Hb 40–60 g/l | 206 (42)           | 56 (46)                       | 63 (36)                        | 37 (45)                      | 50 (44)                       |
| Not per protocol§                         | 96 (19)            | 19 (15)                       | 31 (18)                        | 26 (31)                      | 20 (18)                       |

Hb, haemoglobin; SCD, sickle cell disease.

*Axillary temperature ≥37.5°C.

†497 transfusions were reported in the original trial paper but following publication it was found that one of those transfusions was of a negligible amount.14

‡Severity sign (impaired consciousness and or increased work of breathing).

§No recorded severity signs (impaired consciousness or increased work of breathing), no SCD or haemoglobinuria and Hb ≥40 and <60 g/l.
impact on mortality and whether it reduces unwarranted requests for paediatric transfusions. However, most paediatricians felt that the proposed recommendations for Hb monitoring could be a substantial hurdle for clinical services in some resource-limited hospitals (see accompanying Perspective Paper). As demonstrated in the cost-effectiveness models, major costs to health services are the ‘hotel costs’ (days in hospital) and the price of a blood transfusion. Total costs could be reduced by access to 24-h point-of-care Hb measurements, which would require advocacy to the health services and policy makers from both paediatricians and blood transfusion services.

The strengths of the TRACT trial include its size, multicentre nature (Uganda and Malawi), broad eligibility criteria that enhances its generalisability and enables incorporation of large subgroups with malaria and SCD. In children with uncomplicated severe anaemia, we found a large group of children with undiagnosed SCD. We found no evidence that not transfusing these children (as they did not develop severity features or profound anaemia) resulted in a worse outcome (mortality to Day 28 and Day 180). On this basis, children with either diagnosed or undiagnosed SCD without severity features can be safely managed using a triggered transfusion strategy and thus incorporated into the algorithm.

As noted by the meeting stakeholders most transfusions in the TRACT were given very shortly after screening/identification of a case of severe anaemia (when axillary temperature was recorded), which may not be replicable in usual clinical practice. The relevance of a temperature taken hours before a blood transfusion becomes available was explored by additional analyses. These supported the recommendation that at the time that blood is ordered for a child who has no fever at that time, even if they subsequently developed an intermittent fever (Fig 5), it was still safe (and beneficial) to transfuse with a higher volume. Similarly, for children who have a fever at the time blood is ordered and which then wanes, there is no evidence to support that the requested 20 ml/kg volume would lead to any difference in outcome compared to 30 ml/kg. For children with a persistent fever prescribing 20 ml/kg is also supported by these analyses.

Conclusions

The new evidence provided by the TRACT could lead to important refinements of the WHO transfusion guidelines. First, standardising the definition of severe anaemia, we suggest an Hb <60 g/L. Second, clarifying the definitions of uncomplicated severe anaemia, and severe and complicated anaemia, by using clinical signs of severity. Third, a strong recommendation (based on high quality of evidence) that children with uncomplicated severe anaemia do not require immediate transfusion, irrespective of the underlying causes, but do require monitoring because ~50% will develop severe and life-threatening anaemia requiring subsequent transfusion. Fourth, new recommendations to include a minimal number of clinical and Hb monitoring reviews in a child with severe anaemia (both uncomplicated and complicated) in order to identify those needing an initial or additional transfusion. Fifth, new recommendations on the volume of blood to transfuse, according to fever status when a blood transfusion is ordered, and that either WB or packed RCC (at half the volume) can be used. Finally, the guidelines should make it clear that there is no need for separate recommendations for children with malaria (even those with high parasite burdens), SCD or poor nutritional status. As the trial demonstrated, a high proportion of children presenting with severe anaemia in many of our present study sites had undiagnosed SCD. The group recommended, therefore, that admission to hospital with severe anaemia should prompt clinicians to test for SCD so that long-term follow-up and infection prophylaxis can be put in place.

Funding

The meeting was funded by Imperial College, London, UK though an internally managed Research England Global Challenges Research Funding Scheme (2019–2020). The TRACT trial was Supported by a grant (MR/J012483/1) from the United Kingdom Medical Research Council (MRC) through a concordat with the Department for International Development. The MRC Clinical Trials Unit at University College London receives core support from the MRC (MC_UU_12023/26).

Patient and Public Involvement

Patients and public were not involved in the meeting or the interpretation of the results and development of the transfusion algorithm. We thank all the participants and their families, and staff from all the centres participating in the TRACT trial.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Fig S1. Transfusion volume 30 versus 20 ml/kg comparison by fever status at screening and sickle cell disease status.

Fig S2. Stability of temperature following screening/randomisation.

Fig S3. Heart rate and respiratory rate over time from beginning of first transfusion.

Table S1. Suspected overload events: endpoint review.

References

1. Ala F, Allain JP, Bates I, Boukef K, Boulton F, Brandful J, et al. External financial aid to blood transfusion services in sub-Saharan Africa: a need for reflection. PLoS Medicine 2012;9:e1001309.
2. World Health Organization. Global status report on blood safety and availability 2016. Geneva: World Health Organization; 2017.
3. World Health Organization. Global Database on Blood Safety: Report 2004-2005. Geneva: World Health Organization; 2008.
4. World Health Organization. Pocket Book of Hospital Care for Children, 2nd edn. Geneva: World Health Organization; 2013.
5. Maitland K, Ohuma EO, Mpoya A, Uyoga S, Hassall O, Williams TN. Informing thresholds for paediatric transfusion in Africa: the need for a trial. Wellcome Open Rev. 2019;4:27.
6. Kiguli S, Maitland K, George EC, Olupot-Olupot P, Opoka RO, Engoru C, et al. Anaemia and blood transfusion in African children presenting to hospital with severe febrile illness. BMC Med. 2015;13:21.
7. Opoka RO, Ssemata AS, Oyang W, Nambuya H, John CG, Tumwine JK, et al. High rate of inappropriate blood transfusions in the management of children with severe anaemia in Ugandan hospitals. BMC Health Serv Res. 2018;18:566.
8. Walker RH. Mathematical calculations in transfusion medicine. Clin Lab Med. 1996;16:895–906.
9. Morris KP, Naqvi N, Davies P, Smith M, Lee PW. A new formula for blood transfusion volume in the critically ill. Arch Dis Child. 2005;90:724–8.
10. Olupot-Olupot P, Engoru C, Thompson J, Nteziyaremye J, Chebet M, Ssekyondo T, et al. Phase II trial of standard versus increased transfusion volume in Ugandan children with acute severe anaemia. BMC Med. 2014;12:67.
11. Doctor A, Cholette JM, Remy KE, Argent A, Carson JL, Valentine SL, et al. Recommendations on RBC transfusion in general critically ill children based on hemoglobin and/or physiologic thresholds from the pediatric critical care transfusion and anemia expertise initiative. Pediatr Crit Care Med. 2018;19(Suppl. 1):S98–113.
12. Mpoya A, Kiguli S, Olupot-Olupot P, Opoka RO, Engoru C, Mallewa M, et al. Transfusion and Treatment of severe anemia in African children (TRACT): a study protocol for a randomised controlled trial. Trials. 2015;16:593.
13. Maitland K, Kiguli S, Olupot-Olupot P, Engoru C, Mallewa M, Saramago Goncalves P, et al. Immediate transfusion in African children with uncomplicated severe anaemia. New Engl J Med. 2019;381:407–19.
14. Maitland K, Olupot-Olupot P, Kiguli S, Chagaluka G, Alaroker F, Opoka RO, et al. Transfusion volume for children with severe anaemia in Africa. New Engl J Med. 2019;381:420–31.
15. Uyoga S, Mpoya A, Olupot-Olupot P, Kiguli S, Opoka RO, Engoru C, et al. Haematological quality and age of donor blood issued for paediatric transfusion to four hospitals in sub-Saharan Africa. Vox Sang. 2019;114:340–8.
16. Hendriksen IC, Mwanga-Amumpaire J, von Seidlein L, Mtove G, White LJ, Olaosebikan R, et al. Diagnosing severe falciparum malaria in parasitaemic African children: a prospective evaluation of plasma PfHRP2 measurement. PLoS Medicine 2012;9:e1001297.
17. Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, et al. Mortality after fluid bolus in African children with severe infection. New Engl J Med. 2011;364:2483–95.
18. Olupot-Olupot P, Engoru C, Uyoga S, Muindo R, Macharia A, Kiguli S, et al. High frequency of blackwater fever among children presenting to hospital with severe febrile illnesses in Eastern Uganda. Clin Infect Dis. 2017;64:939–46.
19. American Association of Blood Banks (AABB). Technical Manual, 20th edn. Bethesda, Maryland, USA: AABB; 2020.
## Appendix 1
### Full list of Stakeholder Meeting Attendees

| Name                        | Organisation                                      | Role                                      | Country   |
|-----------------------------|---------------------------------------------------|-------------------------------------------|-----------|
| Dr Deogratias Munube        | Mulago Hospital                                   | President UPA                             | Uganda    |
| Dr Bodo Bongomin            | WHO Uganda                                        | WHO Technical Officer                     | Uganda    |
| Dr Eva Nabawanuka           | Mulago National Referral Hospital                  | Study co-ordinator                        | Uganda    |
| Dr Robert Opoka             | Mulago Hospital                                   | Co-PI TRACT trial                         | Uganda    |
| Prof Peter Olupot Olupot    | Mbale Regional Referral Hospital                   | Co-PI TRACT trial                         | Uganda    |
| Dr Florence Aloroker        | Soroti RRH                                         | Co-PI TRACT trial                         | Uganda    |
| Prof Philippa Musoke        | MUJHU                                             | TRACT DSMB                                 | Uganda    |
| Dr Ritha Nasima             | St Francis Hospital Nsambya                        | Treasurer UPA                             | Uganda    |
| Prof Kathryn Maitland       | KEMRI Wellcome Trust Research Programme           | PI TRACT trial                             | Kenya     |
| Hellen Mnjalla              | KWTRP                                             | TSC Chair/ ETAT Lead                      | Kenya     |
| Christabel Mogaka           | KWTRP                                             | Data Manager                              | Kenya     |
| Prof Thomas Williams        | KWTRP                                             | TRACT co-investigator                      | Kenya     |
| Dr Abubakarr Bah            | Ola During Children’s Hospital, Freetown           | Head of Paediatrics Emergency Unit        | Sierra Leone |
| Prof Elizabeth Molyneux     | Liverpool School of Tropical Medicine             | TSC Chair/ ETAT Lead                      | UK        |
| Dr Christian Umuhozza       | Secretary-General                                  | Rwanda Paediatric Association             | Rwanda    |
| Dr William K. A. Obeng      | Korle Bu Teaching Hospital Accra                   | ETAT Trainer                              | Ghana     |
| Dr Charlyne Kilba          | Korle BU Teaching Hospital, Accra                  | Critical care specialist                   | Ghana     |
| Dr John Appiah            | Paediatric Critical care                          | Senior specialist                          | Ghana     |
| Dr Ismail Ticklay          |                                                  | ETAT Harare                               | Zimbabwe  |
| Dr Yamikani Chimalizeni     | UNIMA College of Medicine                          | TRACT trial Investigator                   | Malawi    |
| Prof Russel Ware            | Cincinnati Children’s Hospital                     | Sickle cell disease Specialist             | United States |
| Dr Roberta Petrucci        | Medicines Sans Frontierie                          | International Paediatric Working Group    | Geneva    |
| Prof Diana Gibb            | MRC Clinical Trials Unit at UCL                   | Professor of Epidemiology                  | UK        |
| Prof Sarah Walker          | MRC/CTU at UCL                                    | Professor of Medical Statistics and Epidemiology | UK      |
| Annabelle South            | MRC/CTU at UCL                                    | Policy and Research Impact Co-ordinator    | UK        |
| Prof Dora Mbanya           | African Society for Blood Transfusion (AfSBT)     | AfSBT President                           | Cameroon  |
| Dr Sophie Uyoga             | KWTRP                                             | TRACT trial Investigator                   | Kenya     |
| Dr Bridon Mbaya            | Malawi Blood Transfusion Service (BTS)            | Medical Director                           | Malawi    |
| Dr ET Mberi                 | Zimbabwe National BTS                              | Director National Blood Transfusion Centre | Zimbabwe  |
| Dr Dorothy Kyeyune         | Uganda BTS                                         | Director                                  | Uganda    |
| Dr Claude T. Tagny         | Haematology and Transfusion Service, University of Yaounde | Director National Blood Transfusion Centre | Cameroon  |
| Dr Salii Diop              | Senegal BTS                                       | Director National Blood Transfusion Centre | Senegal   |
| Dr Faten Moftah            | AfSBT                                             | AfSBT member                              | Egypt     |
| Dr Michael E. Acquah       | Ghana BTS                                         | Director                                  | Ghana     |
| Prof Philip Olatunji       | AfSBT                                             | Professor of Haematology/Vice President, AfSBT | Nigeria |
| Dr Magdalena Lyimo         | Tanzania BTS                                      | Director                                  | Tanzania  |
| Prof Ludovic Anani         | Benin BTS                                         | Former manager, Blood Transfusion Agency of Benin | Benin   |
| Dr Shirley O. Ofori       | Kumasi BTS                                        | Director                                  | Ghana     |
| Dr Charles Engoru          | Soroti RRH                                        | TRACT trial investigator                   | Uganda    |
| Prof Imelda Bates          | Liverpool School of Tropical Medicine             | TRACT trial investigator                   | UK/TRACT trial |

AfSBT, Africa Society for Blood Transfusion; BTS, blood transfusion services; CTU, Clinical Trials Unit; DSMB, Data and Safety Monitoring Board; ETAT, Emergency Triage Assessment and Treatment; KWTRP, Kenya Medical Research Institute Wellcome Trust Research Programme; MRC, UK Medical Research Council; MSF, Médecins Sans Frontières; MUJHU, The Makerere University - Johns Hopkins University Research Collaboration; PI, principal investigator; RRH, Regional Referral Hospital; STM, School of Tropical Medicine; TRACT, Transfusion and Treatment of severe anaemia in African Children Trial; TSC, Trial Steering Committee; UNIMA, University of Malawi; UPA, Uganda Paediatric Association; WHO, World Health Organization.